Skip to main content
  1. Life
  2. Health & Fitness
  3. Holistic Health

Dermal Regeneration for the Treatment of Diabetic Foot Ulcers

See also

Integra LifeSciences Holdings Corporation has announced the enrollment of 307 patients for ramdomized controlled clinical trial comparing the safety and effectiveness of
Integra(R) Dermal Regeneration Template, “an advanced bilayer skin replacement system designed to provide immediate wound closure and permanent skin regeneration, against standard of care for the treatment of diabetic foot ulcers.

Integra LifeSciences specializes in developing treatments for orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.

"Integra Dermal Regeneration Template has a long clinical history of success in burns and scar contracture release, and has the potential to help many people who are suffering with diabetic foot ulcers," stated lead clinical investigator Dr. Vickie Drive. "I look forward to seeing the results from the study, and am hopeful that we will have a new therapy to treat patients with difficult-to-heal wounds."

It is now estimated that 25% of the current 26 million people with diabetes in the US may suffer from disease related foot ulcers at some time during their lifetime. Diabetic foot ulcer is a major complication of diabetes mellitus, and is oftenj a precursor to 84% of allamputations of the lower leg due to the development of macro and micro vascular complications, including failure of the wounds to heal.

"Completion of patient enrollment in the Integra Dermal Regeneration Template diabetic foot ulcer clinical trial is a major milestone for Integra, and marks an important first step toward product commercialization," said Robert D. Paltridge, President, Extremity Reconstruction. "We hope to use the results from this study to receive the expanded indication, which will allow us to provide an additional treatment option to address the increasing prevalence of diabetic foot
ulcers. We look forward to being able to better serve our customers and the diabetic population by providing clinically relevant, cost effective solutions."

The trials will take place at 32 sites, and all patients are followed for up to 28 weeks. Once patient follow-up is complete, this data will be sent to the FDA for eventual product approval.

Advertisement

Life

  • Name my baby
    Canadian couple allows the Internet to name their baby. See the result
    Video
    Name My Baby
  • Prescription drugs
    Americans consume an astonishing 50 percent of the world's prescription drugs
    Prescription Drugs
  • Weight loss
    Health and fitness: How to lose weight and burn extra body fat fast
    Camera
    Weight Loss
  • Twitter fail
    Twitter fail: NYPD's social media outreach campaign backfires
    Twitter Fail
  • Freelancers
    Tricks of the trade: A new study suggests how freelancers can land more jobs
    Job Tips
  • Bad dog
    Sneaky dog vandalizes car tires for over six months before being caught
    Video
    Bad Dog

User login

Log in
Sign in with your email and password. Or reset your password.
Write for us
Interested in becoming an Examiner and sharing your experience and passion? We're always looking for quality writers. Find out more about Examiner.com and apply today!